GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » EV-to-FCF

Centogene NV (Centogene NV) EV-to-FCF : -3.49 (As of May. 04, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Centogene NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Centogene NV's Enterprise Value is $61.13 Mil. Centogene NV's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-17.51 Mil. Therefore, Centogene NV's EV-to-FCF for today is -3.49.

The historical rank and industry rank for Centogene NV's EV-to-FCF or its related term are showing as below:

CNTG' s EV-to-FCF Range Over the Past 10 Years
Min: -58.79   Med: -2.4   Max: 143.92
Current: -3.49

During the past 7 years, the highest EV-to-FCF of Centogene NV was 143.92. The lowest was -58.79. And the median was -2.40.

CNTG's EV-to-FCF is ranked worse than
100% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.875 vs CNTG: -3.49

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Centogene NV's stock price is $0.44285. Centogene NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.710. Therefore, Centogene NV's PE Ratio for today is At Loss.


Centogene NV EV-to-FCF Historical Data

The historical data trend for Centogene NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV EV-to-FCF Chart

Centogene NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial - -11.00 -21.89 -4.15 -1.83

Centogene NV Quarterly Data
Dec17 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.15 -3.01 -2.11 -1.83 -

Competitive Comparison of Centogene NV's EV-to-FCF

For the Diagnostics & Research subindustry, Centogene NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centogene NV's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Centogene NV's EV-to-FCF falls into.



Centogene NV EV-to-FCF Calculation

Centogene NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=61.128/-17.508
=-3.49

Centogene NV's current Enterprise Value is $61.13 Mil.
Centogene NV's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centogene NV  (NAS:CNTG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Centogene NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.44285/-0.710
=At Loss

Centogene NV's share price for today is $0.44285.
Centogene NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.710.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Centogene NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Centogene NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Centogene NV (Centogene NV) Business Description

Traded in Other Exchanges
Address
Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.